Testosterone Science

FDA, Regulation and Guidelines

FDA Holding Public Meeting on Testosterone Use in Menopausal Women

Specific Claim Evaluated

Critical knowledge gaps remain on the effects of testosterone on sexual function, cognition, mood and musculoskeletal health in menopausal women, and no FDA-approved testosterone product exists for women.

Primary Research Supporting or Contradicting the Claim

The global consensus statement finds evidence only for hypoactive sexual desire disorder and insufficient evidence for other outcomes (Davis et al., 2019).

Corrected Evidence-Based Interpretation

The report is correct.

Rationale for Grade

The article reports the FDA position and clinician comments on dosing and compounding accurately, and makes no claim of benefit beyond the evidence.

References

  1. Davis SR, Baber R, Panay N, Bitzer J, Perez SC, Islam RM, Kaunitz AM, Kingsberg SA, Lambrinoudaki I, Liu J, Parish SJ, Pinkerton J, Rymer J, Simon JA, Vignozzi L, Wierman ME. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. PMID
    Supporting excerpt: "The only evidence-based indication for testosterone for women is for HSDD."

Post a Comment

Shared Decision Making

Bring the Evidence to Your Next Consultation

Use our patient resources and questionnaires to prepare questions about symptoms, testing and treatment options for your doctor.